In a real-world study of DLL3 as an SCLC therapeutic target, positive DLL3 expression (defined as ≥25% of tumor cells) was identified in 895/1050 (85%) patients with one specimen and evaluable DLL3 expression; 719/1050 (68%) patients had high DLL3 expression (defined as ≥75% of tumor cells). Here, DLL3 is linked to neoplasm.